Compare CRC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | ADMA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | N/A | 2012 |
| Metric | CRC | ADMA |
|---|---|---|
| Price | $58.70 | $16.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $61.88 | $28.50 |
| AVG Volume (30 Days) | 670.7K | ★ 1.9M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | ★ 723.08 |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $20.03 | $22.13 |
| Revenue Next Year | N/A | $24.12 |
| P/E Ratio | ★ $13.50 | $40.83 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $33.69 | $13.50 |
| 52 Week High | $59.81 | $25.67 |
| Indicator | CRC | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 71.29 | 43.40 |
| Support Level | $54.14 | $15.72 |
| Resistance Level | $59.81 | $16.77 |
| Average True Range (ATR) | 1.74 | 0.64 |
| MACD | 0.30 | 0.03 |
| Stochastic Oscillator | 95.73 | 28.43 |
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.